New drug cocktail takes on advanced liver cancer

NCT ID NCT07479485

Recruiting now Disease control Sponsor: Lepu Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This early-phase trial tests a new drug called MRG006A, combined with immunotherapy and targeted therapy, in 160 people with advanced hepatocellular carcinoma (a type of liver cancer) that cannot be treated with surgery. The study aims to check safety, find the right dose, and see if the combination shrinks tumors. It is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRG006A (a drug that targets PD1 and VEGF, combined with a tyrosine kinase inhibitor)
What this could lead to: If successful, this could offer a new treatment option for people with advanced liver cancer that hasn't responded to other therapies.
What could go wrong: This is an early-phase trial (Phase I/II) with only 160 participants, so it's too soon to know if it will be safe or effective. Combination therapies also carry a higher risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Beijing You An Hospital, Capital Medical University
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100000, China
Henan Cancer Hospital
NOT_YET_RECRUITING

Zhengzhou, Henan, 450003, China
Lishui Central Hospital
NOT_YET_RECRUITING

Lishui, Zhejiang, 323000, China
Mengchao Hepatobiliary Hospital of Fujian Medical University
NOT_YET_RECRUITING

Fuzhou, Fujian, 350001, China
Peking Union Medical College Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100730, China
The Ethics Committee of Cancer Hospital Chinese Academy of Medical Sciences.
RECRUITING

Beijing, Beijing Municipality, 100021, China
The First Affiliated Hospital With Nanjing Medical University
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210006, China
Tianjin Cancer Hospital Airport Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300308, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.